Dihexa: Side Effects & Safety

Dihexa has very limited safety data. The compound emerged from academic research at Washington State University and has not undergone formal clinical trials in humans. Most safety information comes from animal toxicology studies and anecdotal reports. Its extreme potency warrants particular caution.

• Headache: Commonly reported, potentially related to increased neural activity
• Blood pressure changes: Dihexa is an angiotensin IV analog — some users report blood pressure fluctuations. Monitoring is recommended
• Injection site reactions: Standard subcutaneous injection effects (if using injectable form)
• Overstimulation: Anxiety or restlessness reported at higher doses, consistent with enhanced neural activity
• Insomnia: Difficulty sleeping reported, particularly with afternoon or evening dosing

Dihexa carries significant unknowns:

• No human clinical trials: Safety in humans has not been formally evaluated
• HGF/c-Met pathway concerns: The HGF/c-Met signaling pathway is involved in cancer cell growth and metastasis. Amplifying this pathway raises theoretical oncology concerns, though no cancer-promoting effects have been demonstrated in published dihexa research
• Extreme potency: The 10-million-fold potency over BDNF means dosing precision is critical. Errors in concentration or volume could produce outsized effects
• Long-term effects unknown: The effects of sustained synaptogenesis promotion on brain function and structure are not characterized
• Angiotensin system effects: As an AT4 receptor ligand, dihexa interacts with the renin-angiotensin system, which regulates blood pressure and fluid balance

• Active cancer or history of cancer (HGF/c-Met pathway involvement in oncogenesis)
• Uncontrolled hypertension (angiotensin system interactions)
• Pregnancy and breastfeeding
• Concurrent use of ACE inhibitors or ARBs (potential interactions)

Return to the dihexa overview for general information.